{"query":"Aptose Biosciences William Rice CEO leukemia news","follow_up_questions":null,"answer":null,"images":[],"results":[{"url":"https://www.investing.com/news/insider-trading-news/aptose-biosciences-ceo-william-rice-acquires-20000-in-shares-93CH-3743510","title":"Aptose Biosciences CEO William Rice acquires $20000 in shares","content":"William G. Rice, Chair, President, and CEO of Aptose Biosciences Inc. (NASDAQ:APTO), recently acquired 100,000 common shares of the company.","score":0.99995315,"raw_content":null},{"url":"https://investingnews.com/daily/life-science-investing/biotech-investing/aptose-biosciences-clinical-programs-underway/","title":"VIDEO - Aptose Biosciences CEO: Clinical Programs in the Works","content":"In terms of CG-806, Rice said the company has “seen activity” in AML cells in addition to B cell malignancies. He explained that the US Food and","score":0.9998795,"raw_content":null},{"url":"https://www.fiercebiotech.com/biotech/aptose-ceo-props-biotechs-finances-prevent-company-going-bust","title":"CEO props up Aptose's finances to prevent biotech going bust","content":"# Aptose CEO props up biotech's finances to prevent company from going bust. Aptose Biosciences has been thrown a financial lifeline by its own CEO while the leukemia-focused biotech scrambles around for cash to prevent the company from going bust. The Canadian biotech, whose lead clinical-stage asset is an oral kinase inhibitor called tuspetinib, revealed that its CEO and Chairman William Rice, Ph.D., had provided a “short-term cash advance … to support near-term obligations … while it engages in ongoing negotiations with prospective funding partners.”. “The advance is non-interest bearing and the company may repay the advance in whole or in part with no penalty at any time and from time to time,” Aptose explained in a June 17 release. Despite the cash infusion, Aptose warned that if the company doesn’t find more “in the coming days … the corporation does not expect to have sufficient financial resources to fund planned company operations and will have certain alternatives that could include insolvency proceedings.”.","score":0.999608,"raw_content":null},{"url":"https://www.noahai.co/discover/article/7330","title":"Aptose Biosciences Faces Financial Crisis, CEO Steps In with Cash ...","content":"Aptose Biosciences has been thrown a financial lifeline by its own CEO while the leukemia-focused biotech scrambles around for cash to prevent","score":0.9996049,"raw_content":null},{"url":"https://www.aptose.com/news-media/press-releases/detail/336/aptose-reports-third-quarter-2025-results","title":"Aptose Reports Third Quarter 2025 Results","content":"... William G. Rice, Ph.D., Chairman, President and Chief Executive ... Leukemia “Molecular and Translational”: Advances in Biology and","score":0.9986541,"raw_content":null}],"response_time":0.94,"request_id":"4eef64b7-16a4-40b9-a934-e9856688ce49"}